17 active not recruiting. 17 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Active not recruiting 17 |
| Phase 2 | 8 | Active not recruiting 8 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors MNPR-101-PCTA-177Lu - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-10-08 | 2026-09-03 |
| Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-05-30 | 2026-09-03 |
| A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) Pembrolizumab, Intismeran autogene, Placebo - Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 230 | 2024-03-28 | 2026-01-13 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer | Phase 1 | Active not recruiting | BeiGene | 103 | 2024-03-11 | 2026-10-20 |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors LY4101174 - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 490 | 2024-03-05 | 2026-05-22 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers AB598, Zimberelimab, Fluorouracil - Advanced Cancer, Advanced Malignancies | Phase 1 | Active not recruiting | Arcus Biosciences, Inc. | 40 | 2023-10-13 | 2026-11-02 |
| Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations TYRA-300 - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Tyra Biosciences, Inc | 310 | 2022-11-22 | 2026-01-12 |
| A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 UGN-201 - Bladder Cancer, Bladder | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2022-01-24 | 2026-08-06 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 702 | 2020-11-12 | 2026-09-21 |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824 - Urothelial Cancer, Bladder Cancer | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 22 | 2020-07-13 | 2026-09-28 |
| Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients Ascorbic Acid - Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Kansas Medical Center | 12 | 2019-10-17 | 2025-03-25 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab - ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | NeoTX Therapeutics Ltd. | 120 | 2019-10-10 | 2025-11-28 |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG) - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | Noah Hahn, M.D. | 186 | 2017-11-21 | 2026-07-15 |
| A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer Atezolizumab, Gemcitabine, Cisplatin - Bladder Cancer, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2016-12-20 | 2026-10-26 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Cyclophosphamide, TBI-1301, Fludarabine - NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma | Phase 1 | Active not recruiting | University Health Network, Toronto | 22 | 2016-09-01 | 2025-12-03 |
Urinary Bladder Neoplasms (17) · Ovarian Neoplasms (10) · Triple Negative Breast Neoplasms (8) · Stomach Neoplasms (7) · Carcinoma, Transitional Cell (6) · Esophageal Neoplasms (6) · Endometrial Neoplasms (5) · Pancreatic Neoplasms (5) · Uterine Cervical Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Colorectal Neoplasms (4) · Melanoma (4) · Prostatic Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Neoplasms by Site (17) · Urinary Bladder Diseases (17) · Urogenital Diseases (17) · Urologic Diseases (17) · Neoplasms (16) · Urogenital Neoplasms (16) · Urologic Neoplasms (15) · Neoplasms by Histologic Type (12) · Carcinoma (11) · Neoplasms, Glandular and Epithelial (11) · Adnexal Diseases (10) · Digestive System Diseases (10)
Gemcitabine (2) · durvalumab (2) · pembrolizumab (2) · AZD5305 (1) · AZD9833 (1) · Ascorbic Acid (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Fluorouracil (1) · Fulvestrant (1) · Interleukin-2 (1) · Leucovorin (1) · Oxaliplatin (1)
Monopar Therapeutics (2) · Arcus Biosciences, Inc. (1) · AstraZeneca (1) · BeiGene (1) · Cancer Research UK (1) · Eli Lilly and Company (1) · M.D. Anderson Cancer Center (1) · Medicenna Therapeutics, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · NeoTX Therapeutics Ltd. (1) · Noah Hahn, M.D. (1) · Tyra Biosciences, Inc (1) · University Health Network, Toronto (1)
United States (12) · Australia (9) · Spain (5) · Canada (4) · China (3) · France (3) · South Korea (3) · United Kingdom (3) · Israel (2) · Italy (2) · Japan (2) · New Zealand (2) · Poland (2) · Belgium (1) · Chile (1)
Andrea B Apolo, M.D. (1) · Arash Yavari, MBBS (1) · Doug Warner (1) · Johann de Bono, Prof (1) · John Taylor, MD MS (1) · Neema Navai (1) · Nina Merchant (1) · Noah M. Hahn, MD (1) · Prof. Rod Hicks, MD (1) · Samuel Funt, MD (1) · Tal Hetzroni Kedem (1) · Timothy Yap (1)
PMID 35089812, PMID 35929986, PMID 38573872
2023 (3), UL1TR002366 (1)